foselutoclax   Click here for help

GtoPdb Ligand ID: 13366

Synonyms: UBX-1325 | UBX1325
Compound class: Synthetic organic
Comment: Foselutoclax (UBX1325) is a small-molecule inhibitor of BCL-xL that has a senolytic action [2]. Pharmacological elimination of senescent cells is a mechanism that is under investigation to treat pathologies that are promoted in the presence of senescent cells. This senolytic strategy is considered to be an alternative to anti-vascular endothelial growth factor therapies such as aflibercept in degenerative edematous retinal conditions (e.g. diabetic retinopathy) [3].

foselutoclax is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 16
Hydrogen bond donors 5
Rotatable bonds 21
Topological polar surface area 261.23
Molecular weight 1159.69
XLogP 6.88
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)N1C(=C(C(=C1C2=CC=C(C=C2)Cl)C3=CC=CC(=C3)N4CCN(CC4)C5=CC=C(C=C5)NS(=O)(=O)C6=CC=C(C(=C6)S(=O)(=O)C(F)(F)F)N[C@H](CCN7CCC(CC7)OP(=O)(O)O)CSC8=CC=CC=C8)C(=O)O)C
Isomeric SMILES CC1=C(C(=C(N1C(C)C)C2=CC=C(C=C2)Cl)C3=CC(=CC=C3)N4CCN(CC4)C5=CC=C(C=C5)NS(=O)(=O)C6=CC(=C(C=C6)N[C@H](CCN7CCC(CC7)OP(=O)(O)O)CSC8=CC=CC=C8)S(=O)(=O)C(F)(F)F)C(=O)O
InChI InChI=1S/C53H59ClF3N6O10PS3/c1-35(2)63-36(3)49(52(64)65)50(51(63)37-12-14-39(54)15-13-37)38-8-7-9-43(32-38)62-30-28-61(29-31-62)42-18-16-40(17-19-42)59-77(71,72)46-20-21-47(48(33-46)76(69,70)53(55,56)57)58-41(34-75-45-10-5-4-6-11-45)22-25-60-26-23-44(24-27-60)73-74(66,67)68/h4-21,32-33,35,41,44,58-59H,22-31,34H2,1-3H3,(H,64,65)(H2,66,67,68)/t41-/m1/s1
InChI Key FSZILRQCEAUYPL-VQJSHJPSSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Foselutoclax (UBX1325) is a clinical candidate for the elimination of senescent cell-mediated retinal damage in diabetic macular edema and neovascular age-related macular degeneration.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04537884 Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Phase 1 Interventional Unity Biotechnology, Inc.
NCT04857996 Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) Phase 2 Interventional Unity Biotechnology, Inc.
NCT05275205 Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) Phase 2 Interventional Unity Biotechnology, Inc.
NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) Phase 2 Interventional Unity Biotechnology, Inc.